Host-derived (e.g., myeloid cells) VEGF-A may compensate for the lack of tumor-derived VEGF-A (56), which is consistent with the importance of VEGF-A derived from myeloid cells in the early phases of glioma growth (57). This evidence concerns the gene VEGFA and neoplasm.